besides this, shortages and supply chain difficulties by pharma companies with constrained production capacity and a risk of counterfeit products in the market
Starting too high risks unnecessary side effects that can derail your cutting cycle, while staying too conservative may limit results
Retatrutide achieved 24% loss in 48 weeks while semaglutide achieved 17% in 68 weeks and tirzepatide achieved 22% in 72 weeks
So, but specifically for obesity, I think it's in the vein, it's hard to, you should always be careful
18.1% CAGR, supported by employer purchasing and direct-to-consumer access
16,17,18,19 As new indications continue to be developed, GLP-1 drugs demonstrate immense potential in the medical field, with future research expected to expand their therapeutic applications